ARTICLE | Company News
ORCA Therapeutics, VCN Biosciences deal
October 5, 2009 7:00 AM UTC
ORCA received an exclusive, worldwide license to develop and commercialize VCN's T1 oncolytic adenovirus technology for cancer. VCN will receive an undisclosed upfront payment and is eligible for undi...